Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: Lessons from the UK Medical Research Council trials UKALL X and UKALL XI

British Journal of Haematology

Volumn 118, Issue 2, 2002, Pages 445-455

  Chessells, Judith M ^a   Harrison, Georgina ^b   Richards, Susan M ^b   Gibson, Brenda E ^c   Bailey, Clifford C ^d   Hill, Frank G H ^e   Hann, Ian M ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^f Hospital for Sick Children   (United Kingdom)

Author keywords

Childhood lymphoblastic leukaemia; Prognosis; Treatment

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PATIENT CARE; PEDIATRICS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SKULL IRRADIATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKOCYTE COUNT; MALE; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS; TREATMENT FAILURE;

EID: 0036041427     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03647.x     Document Type: Article

References (38)

1. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: A report of the CCG-161 study by the Childrens Cancer Study Group
2. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations
3. How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia
4. The management of high-risk lymphoblastic leukemia in children
5. Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X
6. Sex and treatment outcome in childhood lymphoblastic leukaemia: Report from the MRC UKALL Trials
7. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: Results of MRC UKALL X
8. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12 000 randomized children
9. Levels of 1-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukaemia
10. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: Results of a Dutch phase III study (ALL V)
11. Non-randomized study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia
12. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood)
13. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-97
14. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: A ten-year follow-up
15. Improved therapy for children with acute lymphoblastic leukemia and unfavourable presenting features: A follow-up report on the Childrens Cancer Group Study CCG-106
16. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-95
17. Analysis of the immunophenotype of children treated on the Medical Research Council (MRC) United Kingdom acute lymphoblastic leukaemia trial XI (UKALL XI)
18. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: Results from MRC UKALL XI and MRC ALL97 randomized trials
19. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: Results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol
20. Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI)
21. UKALL XI randomized trial stratified CNS treatments and prospective neurophychological assessment in childhood acute lymphoblastic leukaemia (ALL)
22. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: A Childrens Cancer Group study
23. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: A report on the medical research Council UKALLR1 study
24. Clearance of marrow infiltration after one week of therapy for childhood acute lymphoblastic leukaemia: Clinical importance and the effect of daunorubicin
25. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: Biologic bases for staging, stratification, and treatment
26. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
27. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and Examples
28. Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: Long-term results of St Jude Total Therapy Study X
29. Improved survival with early intensification: Combined results from the Medical Research Council childhood ALL randomized trials, UKALL X and UKALL XI
30. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970-76
31. Effect of protracted high-dose l-asparaginase given as a second exposure in a Berlin-Frankfurt-Munster-based treatment: Results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study: A report from the Associazione Italiana Ematologia Oncologia Pediatrica
32. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster
33. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia
34. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90
35. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01
36. Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity
37. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group Phase III trial
38. Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: Results from Medical Research Council UKALL X and XI